HELP
Cybin D/B/A Helus Pharma
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
10.61
▼ 0.15 (1.39%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.70
Prev close
10.76
Day high
10.74
Day low
10.44
Volume
238.65K
Market cap
$775.17M
P/E (TTM)
—
52W range
3.76 – 15.15
Day trading desk
Gap from prior close
-0.60%
Prior close 10.76
VWAP
10.59
+0.15% from price
Relative volume
0.13×
Quiet session
Session range
2.84%
10.44 – 10.74
Position in range
57%
Mid range
ATR (14D)
0.91
8.62% of price
Prior day high
11.38
PDH
Prior day low
10.51
PDL
Bid / ask spread
—
Quote not published
Session volume
238.08K
Avg 1.79M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-13.67%
-15.2%
1M
-14.37%
-15.5%
3M
+60.03%
+57.0%
6M
+102.10%
+87.5%
YTD
+29.71%
+16.1%
1Y
+65.01%
+49.7%
3Y
-51.02%
-132.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on HELP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
9.42M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | Glavine (Paul) Director of Issuer |
— | 248.00K | — | Direct |
| Sep 30, 26 | So (Eric How-Lun) Director of Issuer |
— | 248.00K | — | Direct |
| Sep 29, 26 | Cavers (Gregory Joseph) Senior Officer of Issuer |
BUY | 3.00K | $38.73K | Indirect |
| Sep 21, 26 | Halstead (Michael I.) Senior Officer of Issuer |
BUY | 100.00K | $1.35M | Direct |
| Sep 15, 26 | Fahel (Gabriel) Senior Officer of Issuer |
BUY | 2.00K | $26.23K | Direct |
| Sep 15, 26 | Fahel (Gabriel) Senior Officer of Issuer |
BUY | 1.00K | $13.12K | Indirect |
| Sep 14, 26 | Halstead (Michael I.) Senior Officer of Issuer |
— | 68.57K | — | Direct |
| Sep 8, 26 | Glavine (Paul) Director of Issuer |
BUY | 100.00K | $1.25M | Direct |
| Sep 8, 26 | Glavine (Paul) Director of Issuer |
— | 230.94K | — | Indirect |
| Sep 8, 26 | Glavine (Paul) Director of Issuer |
— | 230.94K | — | Direct |
| Sep 8, 26 | So (Eric How-Lun) Director of Issuer |
BUY | 100.00K | $1.24M | Direct |
| Sep 4, 26 | So (Eric How-Lun) Director of Issuer |
BUY | 100.00K | $1.21M | Direct |
| Sep 3, 26 | Fahel (Gabriel) Senior Officer of Issuer |
SELL | 27.50K | $323.48K | Direct |
| Sep 3, 26 | Glavine (Paul) Director of Issuer |
BUY | 100.00K | $1.18M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Bartlone (Aaron Frank) |
Senior Officer of Issuer | 225.15K | Acquisition or disposition in the public market |
Fahel (Gabriel) |
Senior Officer of Issuer | 102.96K | Acquisition or disposition in the public market |
Froese (Grant B.) |
Director of Issuer | — | Exercise of rights |
Glavine (Paul) |
Director of Issuer | 4.75M | Exercise of rights |
Halstead (Michael I.) |
Senior Officer of Issuer | 168.57K | Acquisition or disposition in the public market |
Hoskins (Eric William) |
Director of Issuer | — | Exercise of rights |
Inamdar (Amir) |
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | — | Exercise of rights |
Lawson (Mark) |
Director of Issuer | — | Exercise of rights |
Lewis-Hall (Freda C) |
Director of Issuer | — | Exercise of rights |
So (Eric How-Lun) |
Director of Issuer | 4.71M | Exercise of rights |
Fundamentals
Market cap$775.17M
Enterprise value$619.76M
Revenue (TTM)—
Gross profit—
EBITDA$-166.94M
Net income$-171.20M
EPS (TTM)$-4.15
Free cash flow$-82.43M
Total cash$166.36M
Total debt$0
Book value / share$3.91
Shares outstanding73.06M
Float58.04M
Short % of float—
Dividend yield0.00%
Beta (5Y)0.54
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.96
PEG ratio—
Price / sales—
Price / book2.72
EV / revenue—
EV / EBITDA-3.71
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-86.94%
Return on assets-44.38%
Debt / equity—
Current ratio10.97
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | $0 | — |
| Research & development | $86.59M | $39.21M | $32.36M | $25.49M | — | +120.8% |
| Selling, general & admin | $56.00M | $63.91M | $46.47M | $26.03M | — | -12.4% |
| Total operating expense | $142.59M | $103.13M | $78.84M | $51.52M | — | +38.3% |
| Operating income | -$142.59M | -$103.13M | -$78.84M | -$51.52M | — | -38.3% |
| Net interest income | $2.18M | $5.99M | $619.00K | $603.00K | — | -63.6% |
| Pre-tax income | -$148.00M | -$81.59M | -$78.08M | -$47.49M | — | -81.4% |
| Net income | -$148.00M | -$81.61M | -$78.08M | -$47.49M | — | -81.4% |
| Net income to common | -$148.00M | -$81.61M | -$78.08M | -$47.49M | — | -81.4% |
| Basic EPS | -4.25 | -4.04 | -6.96 | -9.88 | — | -5.2% |
| Diluted EPS | -4.25 | -4.04 | -6.96 | -9.88 | — | -5.2% |
| EBIT | -$142.59M | -$103.13M | -$78.84M | -$51.52M | — | -38.3% |
| EBITDA | -$142.47M | -$102.78M | -$78.41M | -$51.27M | — | -38.6% |
| Basic shares | 34.80M | 20.22M | 8.30M | 4.88M | — | +72.1% |
| Diluted shares | 34.80M | 20.22M | 8.30M | 4.88M | — | +72.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Cash & short-term investments | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Accounts receivable | $5.03M | $4.09M | $4.48M | $3.05M | +22.8% |
| Total current assets | $184.52M | $115.45M | $218.54M | $23.18M | +59.8% |
| Property, plant & equipment | $195.00K | $98.00K | $547.00K | $450.00K | +99.0% |
| Goodwill & intangibles | $66.45M | $64.35M | $82.94M | $30.26M | +3.3% |
| Total assets | $251.17M | $179.90M | $302.02M | $53.90M | +39.6% |
| Total current liabilities | $19.38M | $14.90M | $10.10M | $5.66M | +30.0% |
| Total debt | — | $0 | $291.00K | — | — |
| Total liabilities | $19.38M | $14.90M | $10.10M | $5.66M | +30.0% |
| Retained earnings | -$389.54M | -$255.39M | -$226.23M | -$148.15M | -52.5% |
| Shareholder equity | $231.79M | $165.00M | $291.93M | $48.23M | +40.5% |
| Working capital | $165.15M | $100.55M | $208.44M | $17.52M | +64.2% |
| Net tangible assets | $165.34M | $100.65M | $208.99M | $17.97M | +64.3% |
| Shares issued | 51.63M | 21.61M | 20.00M | 5.15M | +138.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$148.00M | -$81.61M | -$78.08M | -$47.49M | -81.4% |
| Depreciation & amortisation | $120.00K | $348.00K | $424.00K | $251.00K | -65.5% |
| Stock-based compensation | $10.86M | $31.28M | $13.89M | $4.69M | -65.3% |
| Change in working capital | -$1.26M | -$6.82M | -$5.03M | -$1.44M | +81.6% |
| Operating cash flow | -$133.27M | -$72.33M | -$68.91M | -$47.43M | -84.3% |
| Capital expenditure | -$1.37M | -$1.40M | -$710.00K | -$3.31M | +1.6% |
| Investing cash flow | -$1.36M | -$1.40M | $6.92M | -$3.31M | +2.4% |
| Financing cash flow | $198.24M | $14.10M | $254.51M | $13.56M | +1,306.4% |
| Free cash flow | -$134.64M | -$73.72M | -$69.62M | -$50.74M | -82.6% |
| End cash position | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $30.76M | $28.89M | $23.86M | $18.85M | $14.99M | +6.5% |
| Selling, general & admin | $18.32M | $18.97M | $17.35M | $10.04M | $9.63M | -3.4% |
| Total operating expense | $49.08M | $47.86M | $41.21M | $28.89M | $24.62M | +2.6% |
| Operating income | -$49.08M | -$47.86M | -$41.21M | -$28.89M | -$24.62M | -2.6% |
| Net interest income | $1.28M | $1.58M | $1.50M | $1.06M | -$1.96M | -18.8% |
| Pre-tax income | -$47.82M | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -1.8% |
| Net income | -$47.82M | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -1.8% |
| Net income to common | -$47.82M | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -1.8% |
| Basic EPS | -0.91 | — | -1.00 | -1.39 | -1.10 | — |
| Diluted EPS | -0.91 | — | -1.00 | -1.39 | -1.10 | — |
| EBIT | -$49.08M | -$47.86M | -$41.21M | -$28.89M | -$24.62M | -2.6% |
| EBITDA | -$49.05M | -$47.83M | -$41.19M | -$28.86M | -$24.59M | -2.6% |
| Basic shares | 52.32M | — | 42.52M | 24.21M | 22.40M | — |
| Diluted shares | 52.32M | — | 42.52M | 24.21M | 22.40M | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $166.37M | $157.26M | $195.13M | $83.75M | $118.69M | — | +5.8% |
| Cash & short-term investments | $166.37M | $157.26M | $195.13M | $83.75M | $118.69M | — | +5.8% |
| Accounts receivable | $5.04M | $5.03M | $4.77M | $4.74M | $4.11M | — | +0.2% |
| Total current assets | $192.69M | $184.52M | $222.90M | $114.58M | $143.65M | — | +4.4% |
| Property, plant & equipment | $180.00K | $195.00K | $186.00K | $125.00K | $82.00K | — | -7.7% |
| Goodwill & intangibles | $66.78M | $66.45M | $67.03M | $66.54M | $67.08M | — | +0.5% |
| Total assets | $259.65M | $251.17M | $290.11M | $181.25M | $210.81M | — | +3.4% |
| Total current liabilities | $17.57M | $19.38M | $16.18M | $13.36M | $14.55M | — | -9.3% |
| Long-term debt | — | — | — | $28.89M | $44.50M | — | — |
| Total debt | — | — | — | $28.89M | $44.50M | $0 | — |
| Total liabilities | $17.57M | $19.38M | $16.18M | $42.25M | $59.05M | — | -9.3% |
| Retained earnings | -$437.35M | -$389.54M | -$342.54M | -$299.87M | -$266.15M | — | -12.3% |
| Shareholder equity | $242.09M | $231.79M | $273.93M | $139.00M | $151.76M | — | +4.4% |
| Working capital | $175.13M | $165.15M | $206.72M | $101.22M | $129.10M | — | +6.0% |
| Net tangible assets | $175.31M | $165.34M | $206.90M | $72.46M | $84.68M | — | +6.0% |
| Shares issued | 61.98M | 51.63M | 49.89M | 26.10M | 23.03M | — | +20.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$47.82M | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -1.8% |
| Depreciation & amortisation | $31.00K | $31.00K | $22.00K | $29.00K | $38.00K | 0.0% |
| Stock-based compensation | $11.57M | $5.26M | $4.48M | $377.00K | $753.00K | +120.2% |
| Change in working capital | -$875.00K | $3.70M | $5.88M | -$7.06M | -$3.77M | -123.6% |
| Operating cash flow | -$37.07M | -$37.29M | -$31.95M | -$34.48M | -$29.55M | +0.6% |
| Capital expenditure | -$320.00K | -$323.00K | -$383.00K | -$436.00K | -$231.00K | +0.9% |
| Investing cash flow | -$320.00K | -$323.00K | -$383.00K | -$436.00K | -$221.00K | +0.9% |
| Financing cash flow | $46.53M | -$169.00K | $143.75M | $27.00K | $54.63M | +27,634.3% |
| Free cash flow | -$37.39M | -$37.61M | -$32.33M | -$34.92M | -$29.78M | +0.6% |
| End cash position | $166.37M | $157.26M | $195.13M | $83.75M | $118.69M | +5.8% |
Options analytics
Put / call volume
0.90
Call-heavy session
Put / call open interest
0.20
Positioning, not flow
Max pain
12.50
+17.8% from spot
ATM implied vol
172.7%
Nearest strike to spot
Skew (10% OTM)
-25.8%
Calls bid over puts
Call volume
78
Contracts, this expiry
Put volume
70
Contracts, this expiry
Heaviest call OI
15.00
1.48K contracts
Heaviest put OI
12.50
608 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.38 | -1.26 | +8.4% |
| Mar 2026 | -1.14 | -1.21 | -5.8% |
| Dec 2025 | -0.98 | -1.36 | -39.8% |
| Sep 2025 | -1.33 | -1.65 | -24.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.95 | 5 | $0 | 0.0% |
| Next quarter | -0.88 | 5 | $0 | 0.0% |
| Current year | -3.72 | 4 | $0 | 0.0% |
| Next year | -2.54 | 2 | $11.07M | 0.0% |
Analyst targets & ownership
Mean target$39.86
High target$68.23
Low target$14.88
Implied upside275.66%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders12.89%
Held by institutions41.10%
Institutions holding112
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.92
-10.97% from price
SMA 20
12.60
-15.78% from price
SMA 50
11.86
-10.53% from price
SMA 100
8.71
+21.87% from price
SMA 200
7.47
+42.05% from price
EMA 12
11.87
-10.62% from price
EMA 26
12.09
-12.27% from price
EMA 50
11.37
-6.67% from price
RSI (14)
36.8
Neutral
MACD (12,26,9)
-0.22
Hist -0.36
ATR (14)
0.91
8.62% of price
Realised vol 30D
74.5%
Annualised
Bollinger upper
14.44
20, 2σ
Bollinger lower
10.76
20, 2σ
50 / 200 cross
Golden
11.86 vs 7.47
Trend bias
Above 200
+42.05%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.16
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
74.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.6%
Peak to trough
Max drawdown 5Y
-95.6%
Peak to trough
ATR 14
0.91
8.62% of price
Beta (reported)
0.54
5Y monthly, from filing
Short interest
Shares short
3.23M
Prior 3.20M
Change vs prior
+0.8%
Shorts adding
% of float
—
—
% of shares out
4.42%
Against total outstanding
Days to cover
2.2
Liquid
Float
58.04M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | Barclays | INITIATED | — | Overweight |
| Aug 20, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 27, 26 | Wells Fargo | INITIATED | — | Overweight |
| Jul 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 1, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Apr 13, 26 | TD Cowen | INITIATED | — | Buy |
| Mar 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 3, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| Nov 20, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Nov 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:38
Split dateSep 19, 2024
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-05
Corporate Changes & Voting Matters
6-K · 2026-10-02
Corporate Changes & Voting Matters
6-K · 2026-10-01
Corporate Changes & Voting Matters
6-K · 2026-09-23
Corporate Changes & Voting Matters
6-K · 2026-09-22
Corporate Changes & Voting Matters
6-K · 2026-09-21
Corporate Changes & Voting Matters
6-K · 2026-09-10
Corporate Changes & Voting Matters
6-K · 2026-09-09
Headlines
Helus Pharma Announces Completion of Legal Name Change
GlobeNewswire · 6d ago
Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data
Simply Wall St. · 13d ago
Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?
Simply Wall St. · 13d ago
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
MarketBeat · 13d ago
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
GlobeNewswire · 15d ago
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
MarketBeat · 15d ago
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
GlobeNewswire · 16d ago
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
GlobeNewswire · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.